Company intelligence / Profile preview

Ambrilia Biopharma Inc.

Montreal, Quebec, Canadabiospace.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Completed Phase 3 trials for Octreotide formulation C2L for acromegaly with positive results showing safety and efficacy, with the ability to replace Sandostatin LAR with less frequent injections and non-inferior efficacy on Growth Hormone and Insulin-like Growth Factor 1

Therapeutic areas: OncologyEndocrinologyInfectious Diseases
Modalities: Peptidessmall molecules
Industry: Biotech

Drug pipeline

4 assets

octreotide (Ambrilia Biopharma Inc.)

Approved

3 more assets in the full pipeline.

Request access →

Partnerships

Merck & Co. ($232 million deal for PPL-100)TEVA Europe (licensing/distribution for Octreotide)Covidien Ltd. (terminated)TaiMed Biologics (took over rights for protease inhibitor and integrase inhibitor programs)

Beyond the preview

Go deeper on Ambrilia Biopharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ambrilia Biopharma Inc..

Explore the full profile